arrow
C

Camilla Zecchetto

university of verona
H指数:15
被引数:1,417

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Futibatinib after Non-Covalent FGFR Inhibitors in FGFR2-Rearranged Intrahepatic Cholangiocarcinoma: Clinical Activity and Resistance Patterns

富替比替尼在FGFR2重排型肝内胆管癌中作为非共价FGFR抑制剂后的临床活性及耐药模式

2026-09-090
PRE
Author Correction: CCL3 predicts exceptional response to TGFβ inhibition in basal-like pancreatic cancer enriched in LIF-producing macrophages

作者更正:CCL3 预测在产生 LIF 的巨噬细胞富集的基底样胰腺癌中,TGFβ 抑制可产生卓越反应

2026-05-220
OA
EGFR ligand Angiogenin predicts response to ALK5 inhibition in pancreatic cancer via a TNF-α paracrine axis in tumor-associated macrophages

EGFR配体血管生成素通过肿瘤相关巨噬细胞中的tnf-α 旁分泌轴预测胰腺癌对ALK5抑制的反应

2026-04-140
OAAI
A randomized phase I/II study of second line treatment with liposomal irinotecan and S-1 versus liposomal irinotecan and 5-fluorouracil in patients with metastatic pancreatic cancer following gemcitabine-based chemotherapy

一项关于脂质体伊立替康联合S-1与脂质体伊立替康联合5-氟尿嘧啶作为二线治疗方案,用于接受吉西他滨为基础化疗后的转移性胰腺癌患者的随机I/II期研究

2024-09-011
PRE
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial

可切除胰腺导管腺癌患者的围手术期NALIRIFOX: 开放标签,多中心,II期nITRO试验

2024-01-016
OA
Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab

靶向FGFR通路不是曲妥珠单抗耐药的非选择性转移性食管胃癌患者的有效治疗策略

2023-03-111
OAAI